This is a working overview of lyophilized solid, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-03. Anything still debated is marked as such rather than presented as settled.
The copper-binding activity of this sequence was described in the 1970s during studies of liver tissue and plasma factors. Early work identified the peptide as a component that influenced copper uptake by cells and that appeared in wound fluid. Later investigations examined its presence across species, reporting the same chain in human and animal samples. A decline in measured concentration with age became a recurring observation, although the underlying causes remain incompletely characterised.
Published studies describe the complex in several research contexts, including collagen synthesis, antioxidant behaviour, and wound repair models. Much of this work is conducted in cultured cells or in small animal systems, and the findings are frequently cited in reviews of copper peptides. Direct clinical evidence in humans is comparatively limited, and reported outcomes vary with formulation and study design. Whether free chain or metal-bound form was used is not always stated, a point that complicates comparison between reports.
GHK-Cu is a coordination complex formed between the peptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The unbound chain, abbreviated GHK, consists of three amino acids and occurs naturally in human plasma, saliva, and urine. Binding of the metal is mediated mainly by the imidazole nitrogen of the histidine residue together with backbone amides, producing a stable chelate. Ingredient nomenclature often lists the same substance as copper tripeptide-1. Its charge and solubility behaviour differ from those of the metal-free chain.
Material described in research and cosmetic supply chains is typically a synthetic peptide supplied as a lyophilized powder. Purity is commonly reported through chromatographic separation, often at 95 percent or higher, while copper content is confirmed by separate elemental analysis. Batch variation in color and solubility can reflect residual counter-ions, moisture, or partial oxidation of the peptide. Because the complex is not a single regulatory entity, specifications differ between suppliers and are not standardized internationally.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide binds copper through its histidine imidazole nitrogen, its terminal amino group, and a deprotonated amide nitrogen, creating a stable chelate ring. The resulting complex carries a distinctive blue to blue-violet color, which arises from copper d-d electronic transitions. In the solid state it is usually handled as a powder, while in solution the complex can dissociate and re-form depending on pH and competing ligands. The name copper tripeptide-1 is widely used in ingredient listings.
The tripeptide was first isolated from a human plasma filtrate in 1973 during studies of tissue repair factors. Later work detected the free peptide and its copper complex in saliva, urine, and wound fluid, suggesting a natural role in tissue remodeling. Plasma concentrations reported in early literature decline with age, a pattern often cited in discussions of skin aging. Whether these endogenous levels are directly functional or largely incidental remains an open question. The peptide sequence is conserved across mammalian species.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Copper(II) peptide complex | Coordination compound rather than a simple salt |
| Peptide sequence | Glycyl-L-histidyl-L-lysine | Abbreviated GHK in most literature |
| Molecular formula | C14H22N6O4Cu | Reported for the 1:1 complex |
| Principal binding site | Histidine imidazole nitrogen | Backbone amides contribute additional coordination |
| Common synonym | Copper tripeptide-1 | Used in ingredient and product labelling |
The peptide was first isolated from human albumin in 1973 by Loren Pickart, who later described its copper-binding behavior. Early work linked the complex to wound healing and tissue remodeling. Plasma levels of GHK decline with age, a pattern that stimulated interest in topical and supplemental applications. Researchers have reported that the tripeptide influences collagen synthesis, antioxidant defense, and inflammatory signaling in cell and animal models. Human clinical evidence remains limited and often relies on small studies.
Commercial products list GHK-Cu as copper tripeptide-1, a cosmetic ingredient. Formulators value its blue color and water solubility, which allow incorporation into serums, creams, and masks. Regulatory treatment varies: in the United States it appears in cosmetics, while some jurisdictions classify certain claims as drug-like. The compound is not an approved drug for any indication. Studies continue to examine its effects on skin, hair, and wound repair, but dosage, delivery, and long-term safety questions remain open.
Purity assessment typically involves high-performance liquid chromatography for the peptide and atomic spectroscopy for copper content. The ratio of copper to peptide is a key quality parameter; a value near one indicates proper stoichiometry. Impurities can include free peptide, copper salts, and truncated sequences from synthesis. Because the complex is dynamic, sample preparation and mobile-phase conditions can shift the observed species. Reported purity values therefore depend on the analytical method and should be interpreted with that context.
Characterizing GHK-Cu requires methods that distinguish the intact complex from free peptide and unbound copper. UV-visible absorption around 600 nm provides a rapid check for copper coordination, while circular dichroism reports on peptide secondary structure. Mass spectrometry confirms the peptide mass and can detect copper adducts under carefully controlled conditions. Electron paramagnetic resonance is particularly informative for Cu(II) because it reveals the ligand field symmetry. No single technique fully defines the complex, so laboratories combine orthogonal methods.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry to confirm the expected mass. Copper content is measured separately by inductively coupled plasma optical emission spectrometry or atomic absorption spectroscopy, because the peptide assay alone does not establish the metal-to-peptide ratio. Visible spectroscopy provides a rapid check on complex integrity through the absorption band in the visible region. Agreement between the peptide assay and the copper assay is the practical test of whether a sample is the intended complex rather than a mixture.
Aqueous solutions of GHK-Cu are less stable than the dry powder. The peptide backbone is vulnerable to hydrolysis at extreme pH, and copper can be stripped from the complex by strong chelating agents such as EDTA or citrate. Oxidising agents and high concentrations of ascorbic acid can reduce copper(II) and change the complex, which is one reason formulators often keep such ingredients in separate phases. How quickly these changes occur under real storage conditions depends on pH, buffer, temperature and packaging, and quantitative data on the subject are limited.
== Function == SENP1 catalyzes maturation of SUMO protein (small ubiquitin-related modifier). SENP1 causes hydrolysis of a peptide bond of SUMO in the conserved sequence Gly-Gly-|-Ala-Thr-Tyr at the C-terminus, which can then be conjugated to other proteins (sumoylation). In vertebrates there are three members of the family of SUMO: SUMO-1, -2 and -3. SENP1 can catalyze the maturation of any of these three. This conjugation of SUMO toward other proteins is similar to ubiquitination, however these modifications can lead to different outcomes depending on the type of protein being modified.
== Pharmacokinetics == Plasma picamilon concentrations are generally in the 500–3000 μg/L range during the first few hours after single oral doses of 50–200 mg. It exhibits linear pharmacokinetics with a half-life of 1–2 hours. As discussed previously, the drug undergoes hydrolysis to GABA and nicotinic acid. Urinary excretion of parent drug and the two metabolites accounts for up to 79% of a single dose.
After the expression of the gene product, it may be necessary to purify the expressed protein; however, separating the protein of interest from the great majority of proteins of the host cell can be a protracted process. To make this purification process easier, a purification tag may be added to the cloned gene. This tag could be histidine (His) tag, other marker peptides, or a fusion partners such as glutathione S-transferase or maltose-binding protein. Some of these fusion partners may also help to increase the solubility of some expressed proteins. Other fusion proteins such as green fluorescent protein may act as a reporter gene for the identification of successful cloned genes, or they may be used to study protein expression in cellular imaging.
=== Medical management === It is often possible to manage severe malnutrition within a person's home, using ready-to-use therapeutic foods. In people with severe malnutrition complicated by other health problems, treatment in a hospital setting is recommended. In-hospital treatment often involves managing low blood sugar, maintaining adequate body temperature, addressing dehydration, and gradual feeding. Routine antibiotics are usually recommended because malnutrition weakens the immune system, causing a high risk of infection. Additionally, broad spectrum antibiotics are recommended in all severely undernourished children with diarrhea requiring admission to hospital. A severely malnourished child who appears to have dehydration, but has not had diarrhea, should be treated as if they have an infection. Among malnourished people who are hospitalized, nutritional support improves protein intake, calorie intake, and weight.
===== History of Vitatron ===== 1956: Vitatron founded 1962: First Implantable pacemakers 1981: Microprocessor-driven, software-based pacemaker (DPG1) 1982: Rate Responsive pacemaker (TX1) 1984: Quintech DDD with automatic upper rate behavior ("mode switch") 1988: Daily Learn algorithm (Rhythmyx) 1997: First upgradeable pacemaker system with dedicated AF diagnostics, rate and rhythm control therapy. 2003: Vitatron goes digital: 1st Vitatron C-Series, the world's first fully digital pacemaker. 2004: 2nd Vitatron C-Series, digital, fast pacemaker. 2004: Vitatron T-Series: The full picture, digital pacemaker system. 2005: Vitatron C-Series, A3 models, a new top line range of digital pacemakers for bradycardic patients.
Sources: en.wikipedia.org
Use of lithium for mental disorders was re-established (on a different theoretical basis) in 1948 by John Cade in Australia. Lithium carbonate is on the World Health Organization's List of Essential Medicines, and is available as a generic medication. In 2023, it was the 187th most commonly prescribed medication in the United States, with more than 2 million prescriptions. It appears to be underused in older people, and in certain countries, for reasons including patients' negative beliefs about lithium.
== History == Studies in the early 1960s showed that administration of α-MSH caused sexual arousal in rats, sparking interest in α-MSH. In the 1980s, scientists at University of Arizona began developing α-MSH and analogs as potential sunless tanning agents. They synthesized and tested several analogs, including peptides they subsequently named melanotan-I and melanotan II. Very early in the process, one of the scientists, Mac Hadley, was conducting self-experiments with melanotan II. He mistakenly injected himself with twice the intended dose and experienced an eight-hour erection, along with nausea and vomiting. To pursue the tanning agent, melanotan-I was licensed by Competitive Technologies, a technology transfer company operating on behalf of University of Arizona, to an Australian startup called Epitan, which changed its name to Clinuvel in 2006. To pursue the sexual dysfunction agent, melanotan II was licensed by Competitive Technologies to Palatin Technologies. Palatin ceased development of melanotan II in 2000, and synthesized, patented, and began to develop bremelanotide, a likely metabolite of melanotan II that differs from melanotan II in that it has a hydroxyl group where melanotan II has an amide. Competitive Technologies sued Palatin for breach of contract and to try to claim ownership of bremelanotide; the parties settled in 2008, with Palatin retaining rights to bremelanotide, returning rights to melanotan II to Competitive Technologies, and paying $800,000.
=== Medications === Some medications are known to cause muscle atrophy, usually due to direct effect on muscles. This includes glucocorticoids causing glucocorticoid myopathy or medications toxic to muscle such as doxorubicin.
==== 2900–2999 ==== Farm and Conservation Grant (Amendment) Regulations 1993 (S.I. 1993/2900) Farm and Conservation Grant (Variation) Scheme 1993 (S.I. 1993/2901) Medicines (Pharmacies) (Applications for Registration and Fees) Amendment Regulations 1993 (S.I. 1993/2902) Motor Vehicles (Type Approval and Approval Marks) (Fees) (Amendment) Regulations 1993 (S.I. 1993/2903) Occupational Pensions (Revaluation) Order 1993 (S.I. 1993/2904) Family Provision (Intestate Succession) Order 1993 (S.I. 1993/2906) Western Isles Islands Council (Brevig) Harbour Empowerment Order 1993 (S.I. 1993/2908) Transport Act 1985 (Modifications in Schedule 4 to the Transport Act 1968) (Further Modification) (Amendment) Order 1993 (S.I. 1993/2909) Education (Mandatory Awards) (No. 2) Regulations 1993 (S.I. 1993/2914) Education (Student Loans) (No.2) Regulations 1993 (S.I. 1993/2915) Forth Ports Authority (Dissolution) Order 1993 (S.I. 1993/2916) A43 Trunk Road (Weldon Bypass) Order 1993 (S.I. 1993/2917) A43 Trunk Road (Stamford Road, Northamptonshire) (Detrunking) Order 1993 (S.I. 1993/2918) Firearms (Amendment) Act 1988 (Firearms Consultative Committee) Order 1993 (S.I. 1993/2919) Bovine Embryo Collection and Transfer (Fees) Regulations 1993 (S.I. 1993/2920) Bovine Embryo Collection and Transfer Regulations 1993 (S.I. 1993/2921) Consumer Credit (Exempt Agreements) (Amendment) (No. 2) Order 1993 (S.I. 1993/2922) Imitation Dummies (Safety) Regulations 1993 (S.I. 1993/2923) Hill Livestock (Compensatory Allowances) (Amendment) (No. 2) Regulations 1993 (S.I.
Sources: en.wikipedia.org
GHK denotes the unbound chain of three amino acids. GHK-Cu describes the form in which a copper(II) ion is held by that chain. The two are not interchangeable in solution, since charge, molecular weight, and reactivity differ.
The chain occurs in human plasma, saliva, and urine. Measured amounts are reported to fall with age. Copper binding by the sequence is treated as part of normal metal handling in tissue.
The bound copper(II) centre contributes to redox behaviour and to stability under physiological conditions. Free copper ions can participate in reactions that generate reactive species, while chelated metal is generally more controlled. The chain may also serve as a carrier for copper in experimental systems.
It is a complex of the tripeptide glycyl-L-histidyl-L-lysine with a copper(II) ion. The peptide coordinates the metal through its histidine, amino terminus, and an amide nitrogen. It is often listed simply as copper tripeptide-1.